# US 2013/0274469 A1 · Isoxazolo-pyridine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274469 A1
- Document ID: US20130274469A1
- Status: Published application
- Kind: A1
- Application number: 13/916,317
- Filed: 2013-06-12
- Published: 2013-10-17
- Earliest claimed: 2007-12-04
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Bernd Buettelmann; Roland Jakob-Roetne; Henner Knust; Matthew C. Lucas; Andrew Thomas
- Web page: https://patentgrep.com/patent/US20130274469A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 491/08: Bridged systems
- C07D 491/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

## Claims

### Claim 1

A compound of formula I
wherein
X is O or NH;
R1 is phenyl, optionally substituted with 1, 2 or 3 halo,
R2 is H or CH3 or CF3;
R3, R4, R5, and R6 are H;
C1-7alkyl, optionally substituted with one or more halo, cyano, or hydroxy,
C1-7alkoxy, optionally substituted with one or more halo,
CN,
halo,
NO2,
S—C1-7alkyl,
S(O)—C1-7alkyl
benzyloxy, optionally substituted with one or more E,
—C(O)—Ra, wherein Ra is hydroxy, C1-7alkoxy, C1-7alkyl, phenoxy or phenyl,
3- to 7-membered heterocyclyl, optionally substituted with one or more A,
—C(O)—NRbRc, wherein Rb and Rc are each independently
H,
C1-7alkyl, optionally substituted with one or more halo, methyl, —(CH2)t-hydroxy, or cyano,
—(CH2)t—C3-7cycloalkyl, optionally substituted by one or more B,
and t is 0, 1, 2, 3, 4, 5 or 6,
—(CH2)u—O—C1-7alkyl, wherein u is 2, 3, 4, 5 or 6,
—CHRi—C(O)ORii, wherein Ri is H, benzyl or C1-4alkyl, and Rii is H or C1-7alkyl,
—S(O)2—C1-7alkyl,
—S(O)2—C3-7cycloalkyl,
—(CH2CH2O)vRiii, wherein v is from 1 to 3, and Riii is H or C1-7alkyl,
—(CH2)w-heteroaryl or —(CH2)w-aryl, each optionally substituted by one or more E, and wherein w is 0, 1, 2, 3, or 4,
—(CH2)x-heterocyclyl, wherein x is 0, 1, 2, 3 or 4, and wherein heterocyclyl is optionally substituted by one or more
oxo,
C1-7alkyl,
C3-7cycloalkyl, optionally substituted with one or more B,
CN,
benzyl, optionally substituted with one or more E,
—(CH2)y—C(O)Riv, wherein y is 0, 1, 2, 3 or 4, and Riv is hydroxy, C1-7alkyl, or C1-7alkoxy,
—(CH2)z—C(O)NRvRvi, —(CH2)zNRvRvi—C(O)—C1-7alkyl or —(CH2)zNRvRvi—C(O)—O—C1-7alkyl, wherein z is 0, 1, 2, 3 or 4, and Rv and Rvi are independently
hydrogen,
C1-7alkyl, optionally substituted by one or more halo, OH or CN,
C3-7cycloalkyl, optionally substituted by one or more B,
5- or 6-membered heterocyclyl, optionally substituted by one or more A, or
Rv and Rvi together with the nitrogen to which they are bound form a 5- or 6-membered heterocycloalkyl, optionally substituted by one or more A, or
Rb and Rc together with the nitrogen to which they are bound form a heterocyclyl or heteroaryl moiety, optionally substituted with one or more A, or
Rb and Rc together with the nitrogen to which they are bound form a 7- to 12-membered spirocyclic heterocycle, optionally substituted with one or more A;
with the proviso that Rb and Rc are not simultaneously H, and at least one of R3, R5, and R6 being other than hydrogen;
A is hydroxy, oxo, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, halo, or CN;
B is halo, hydroxy, CN, C1-4alkyl, benzyloxy, or C1-4haloalkyl; and
E is halo, CN, NO2, hydroxy, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, C1-7cyanoalkyl, C1-7haloalkoxy, or C3-7cycloalkyl;
with the proviso that at least one of R3, R5, and R6 being other than hydrogen;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R3 and R6 are H, halo, CN or C1-7alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R4 is
H,
C1-7alkyl, optionally substituted with one or more halo, cyano, or hydroxy,
C1-7alkoxy, optionally substituted with one or more halo,
CN,
halo,
NO2,
S—C1-7alkyl,
S(O)—C1-7alkyl
benzyloxy, optionally substituted with one or more E,
—C(O)—Ra, wherein Ra is hydroxy, C1-7alkoxy, C1-7alkyl, phenoxy or phenyl,
3- to 7-membered heterocyclyl, optionally substituted with one or more A,
—C(O)—NRbRc, wherein Rb and Rc are each independently
H,
C1-7alkyl, optionally substituted with one or more halo, methyl, —(CH2)t-hydroxy, or cyano,
—(CH2)t—C3-7cycloalkyl, optionally substituted by one or more B, and t is 0, 1, 2, 3, 4, 5 or 6,
—(CH2)u—O—C1-7alkyl, wherein u is 2, 3, 4, 5 or 6,
—CHRi—C(O)ORii, wherein Ri is H, benzyl or C1-4alkyl, and Rii is H or C1-7alkyl,
—S(O)2—C1-7alkyl
—S(O)2—C3-7cycloalkyl
—(CH2CH2O)vRiii, wherein v is from 1 to 3, and Riii is H or C1-7alkyl,
—(CH2)w-heteroaryl or —(CH2)w-aryl, each optionally substituted by one or more E, and wherein w is 0, 1, 2, 3, or 4,
—(CH2)x-heterocyclyl, wherein x is 0, 1, 2, 3 or 4, and wherein heterocyclyl is optionally substituted by one or more
oxo,
C1-7alkyl,
C3-7cycloalkyl, optionally substituted with one or more B,
CN,
benzyl, optionally substituted with one or more E,
—(CH2)y—C(O)Riv, wherein y is 0, 1, 2, 3 or 4, and Riv is hydroxy, C1-7alkyl, or C1-7alkoxy,
—(CH2)z—C(O)NRvRvi, —(CH2)zNRvRvi—C(O)—C1-7alkyl or (CH2)zNRvRvi—C(O)—O—C1-7alkyl, wherein z is 0, 1, 2, 3 or 4 and Rv and Rvi are independently
hydrogen,
C1-7alkyl, optionally substituted by one or more halo, OH or CN,
C3-7cycloalkyl, optionally substituted by one or more B,
5- or 6-membered heterocyclyl, optionally substituted by one or more A, or
Rv and Rvi together with the nitrogen to which they are bound form a 5- or 6-membered heterocycloalkyl, optionally substituted by one or more A, or
Rb and Rc together with the nitrogen to which they are bound form a heterocyclyl or heteroaryl moiety, optionally substituted with one or more A, or
Rb and Rc together with the nitrogen to which they are bound form a 7- to 12-membered spirocyclic heterocycle, optionally substituted with one or more A;
with the proviso that Rb and Rc are not simultaneously H,
A is hydroxy, oxo, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, halo, or CN;
B is halo, hydroxy, CN, C1-4alkyl, benzyloxy, or C1-4haloalkyl; and
E is halo, CN, NO2, hydroxy, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, C1-7cyanoalkyl, C1-7haloalkoxy, or C3-7cycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R4 is
—C(O)—NRbRc, wherein Rb and Rc are each independently
H,
C1-7alkyl, optionally substituted with one or more halo, methyl, —(CH2)t-hydroxy, or cyano,
—(CH2)t—C3-7cycloalkyl, optionally substituted by one or more B, and t is 0, 1, 2, 3, 4, 5 or 6,
—(CH2)u—O—C1-7alkyl, wherein u is 2, 3, 4, 5 or 6,
—CHRi—C(O)ORii, wherein Ri is H, benzyl or C1-4alkyl, and Rii is H or C1-7alkyl,
—S(O)2—C1-7alkyl,
—S(O)2—C3-7cycloalkyl,
—(CH2CH2O)vRiii, wherein v is from 1 to 3, and Riii is H or C1-7alkyl,
—(CH2)w-heteroaryl or —(CH2)w-aryl, each optionally substituted by one or more E, and wherein w is 0, 1, 2, 3, or 4,
—(CH2)x-heterocyclyl, wherein x is 0, 1, 2, 3 or 4, and wherein heterocyclyl is optionally substituted by one or more
oxo,
C1-7alkyl,
C3-7cycloalkyl, optionally substituted with one or more B,
CN,
benzyl, optionally substituted with one or more E,
—(CH2)y—C(O)Riv, wherein y is 0, 1, 2, 3 or 4, and Riv is hydroxy, C1-7alkyl, or C1-7alkoxy,
—(CH2)z—C(O)NRvRvi, —(CH2)zNRvRvi—C(O)—C1-7alkyl or
—(CH2)zNRvRvi—C(O)—O—C1-7alkyl, wherein z is 0, 1, 2, 3 or 4, and Rv and Rvi are independently
hydrogen,
C1-7alkyl, optionally substituted by one or more halo, OH or CN,
C3-7cycloalkyl, optionally substituted by one or more B,
5- or 6-membered heterocyclyl, optionally substituted by one or more A, or
Rv and Rvi together with the nitrogen to which they are bound form a 5- or 6-membered heterocycloalkyl, optionally substituted by one or more A, or
Rb and Rc together with the nitrogen to which they are bound form a heterocyclyl or heteroaryl moiety, optionally substituted with one or more A, or
Rb and Rc together with the nitrogen to which they are bound form a 7- to 12-membered spirocyclic heterocycle, optionally substituted with one or more A
with the proviso that Rb and Rc are not simultaneously H,
A is hydroxy, oxo, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, halo, or CN;
B is halo, hydroxy, CN, C1-4alkyl, benzyloxy, or C1-4haloalkyl; and
E is halo, CN, NO2, hydroxy, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, C1-7cyanoalkyl, C1-7haloalkoxy, or C3-7cycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R4 is
H,
C1-7alkyl, optionally substituted with one or more halo, cyano, or hydroxy, C1-7alkoxy, optionally substituted with one or more halo,
CN,
halo,
NO2,
S—C1-7alkyl,
S(O)—C1-7alkyl, or
benzyloxy, optionally substituted with one or more E, and
E is halo, CN, NO2, hydroxy, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, C1-7cyanoalkyl, C1-7haloalkoxy, or C3-7cycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R4 is
—C(O)—Ra, wherein Ra is hydroxy, C1-7alkoxy, C1-7alkyl, phenoxy or phenyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R4 is benzyloxy optionally substituted with one or more E and
E is halo, CN, NO2, hydroxy, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, C1-7cyanoalkyl, C1-7haloalkoxy, or C3-7cycloalkyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R4 is
3- to 7-membered heterocyclyl, optionally substituted with one or more A,
wherein A is hydroxy, oxo, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, halo, or CN;
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R4 is oxethenanyl substituted with one OH.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R5 is
H,
C1-7alkyl, optionally substituted by one or more halo, hydroxy or CN,
benzyloxy, optionally substituted with one or more E,
3- to 7-membered heterocyclyl, optionally substituted with one or more A,
—C(O)—NRbRc, wherein Rb and Rc are each independently H, or
3-7-membered heterocycloalkyl, optionally substituted with one or more A, and
A is hydroxy, oxo, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, halo, or CN;
E is halo, CN, NO2, hydroxy, C1-7alkyl, C1-7alkoxy, C1-7haloalkyl, C1-7hydroxyalkyl, C1-7cyanoalkyl, C1-7haloalkoxy, or C3-7cycloalkyl.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R5 is H or trifluoromethyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R4 is H.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R4 is CN.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R4 is halo.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R4 is NO2.

### Claim 16 (depends on 1)

The compound of claim 1, wherein R1 is phenyl optionally substituted with one or two halo.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R2 is methyl or trifluoromethyl.

### Claim 18 (depends on 1)

The compound of claim 1, wherein R3 is H, halo, CN, or C1-7alkyl.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R3 is H, CN, or C1-4alkyl.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R3 is H, CN, or methyl.

### Claim 21 (depends on 1)

The compound of claim 1, wherein R6 is H, halo, CN, or C1-7alkyl.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R6 is H, halo, or C1-4alkyl.

### Claim 23 (depends on 22)

The compound of claim 22, wherein R6 is H, Br, or C1-4alkyl.

### Claim 24 (depends on 23)

The compound of claim 23, wherein R6 is H, Br or methyl.

### Claim 25 (depends on 1)

The compound of claim 1, wherein R4 is C(O)NRbRc, wherein Rb and Rc together with the N to which they are bound form a heterocyclyl moiety optionally substituted with one or more A.

### Claim 26 (depends on 1)

The compound of claim 1, wherein R4 is C(O)NRbRc, wherein Rb and Rc together with the N to which they are bound form a 7- to 12-membered spirocyclic heterocycle optionally substituted with one or more A.

### Claim 27 (depends on 1)

The compound of claim 1, wherein R3, R4, R5, and R6 are not simultaneously H.

### Claim 28 (depends on 1)

The compound of claim 1, selected from the group consisting of:
2-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyridine;
4-benzyloxy-2-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyridine;
1-methyl-2′-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-1,2,3,6-tetrahydro-[4,4′]bipyridinyl;
2-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-N-(2,2,2-trifluoro-ethyl)-isonicotinamide;
2-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-N-(tetrahydro-pyran-4-yl)-isonicotinamide;
2-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-N-(tetrahydro-pyran-4-yl)-nicotinamide;
6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-4-trifluoromethyl-nicotinic acid;
N-isopropyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-4-trifluoromethyl-nicotinamide;
6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-N-(tetrahydro-pyran-4-yl)-4-trifluoromethyl-nicotinamide;
5-bromo-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-nicotinic acid methyl ester;
5-bromo-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-N-(tetrahydro-pyran-4-yl)-nicotinamide and
a pharmaceutically acceptable salt or ester thereof.

### Claim 29 (depends on 1)

The compound of claim 1, selected from the group consisting of:
5-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-N-(tetrahydro-pyran-4-yl)-nicotinamide;
5-bromo-2-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-N-(tetrahydro-pyran-4-yl)-nicotinamide;
5-bromo-N-isopropyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-nicotinamide;
N-isopropyl-5-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-nicotinamide;
2-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-nicotinic acid ethyl ester;
6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyridine-2-carbonitrile and
a pharmaceutically acceptable salt or ester thereof.

### Claim 30 (depends on 1)

The compound of claim 1 wherein said compound is 5-methyl-6-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-N-(tetrahydro-pyran-4-yl)-nicotinamide or a pharmaceutically acceptable salt thereof.
